ELIGARD leuprorelin acetate 45 mg modified release injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

eligard leuprorelin acetate 45 mg modified release injection syringe

mundipharma pty ltd - leuprorelin acetate, quantity: 45 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.,central precocious puberty (cpp),eligard 45mg 6 month is indicated for the treatment of children 2 years of age and older with central precocious puberty (cpp).

LUCRIN DEPOT leuprorelin acetate 45mg powder for suspension prefilled dual-chamber syringe injection Australia - English - Department of Health (Therapeutic Goods Administration)

lucrin depot leuprorelin acetate 45mg powder for suspension prefilled dual-chamber syringe injection

abbvie pty ltd - leuprorelin acetate, quantity: 45 mg - injection - excipient ingredients: mannitol; polylactic acid; stearic acid; glacial acetic acid; carmellose sodium; polysorbate 80; water for injections - lucrin depot is indicated for the palliative treatment of metastatic or locally advanced prostate cancer.

Lucrin Depot Paediatric leuprorelin acetate 30 mg powder for injection prefilled dual chamber syringe Australia - English - Department of Health (Therapeutic Goods Administration)

lucrin depot paediatric leuprorelin acetate 30 mg powder for injection prefilled dual chamber syringe

abbvie pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: mannitol; polylactic acid - lucrin depot paediatric 30 mg 3-month pds injection is indicated in the treatment of children with central precocious puberty (cpp).

LUCRIN DEPOT 4-MONTH Leuprorelin acetate 30mg powder for injection prefilled dual-chamber syringe with 23 G needle Australia - English - Department of Health (Therapeutic Goods Administration)

lucrin depot 4-month leuprorelin acetate 30mg powder for injection prefilled dual-chamber syringe with 23 g needle

abbvie pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: mannitol; polylactic acid - in the palliative treatment of metastatic or locally extensive prostate cancer (stage c and d).

ELIGARD leuprorelin acetate 30mg modified release injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

eligard leuprorelin acetate 30mg modified release injection syringe

mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

ELIGARD leuprorelin acetate 22.5mg modified release injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

eligard leuprorelin acetate 22.5mg modified release injection syringe

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

ELIGARD leuprorelin acetate 7.5mg modified release injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

eligard leuprorelin acetate 7.5mg modified release injection syringe

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1

ELIGARD 45 MG Israel - English - Ministry of Health

eligard 45 mg

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

BI ELIGARD CP (Eligard 3 month 22.5mg and MPL-Bicalutamide 50mg, 28 pack) Australia - English - Department of Health (Therapeutic Goods Administration)

bi eligard cp (eligard 3 month 22.5mg and mpl-bicalutamide 50mg, 28 pack)

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.

BI ELIGARD CP (Eligard 1 month 7.5mg and MPL-Bicalutamide 50mg, 28 pack) Australia - English - Department of Health (Therapeutic Goods Administration)

bi eligard cp (eligard 1 month 7.5mg and mpl-bicalutamide 50mg, 28 pack)

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.